GENFIT reported a net profit of €1.5 million for 2024, driven by €67.0 million in revenues including a €48.7 million milestone payment and royalties from Iqirvo® (elafibranor) sales in PBC.
Roswell Park Comprehensive Cancer Center is conducting clinical trials for new KRAS-targeting agents that offer alternative approaches to treating KRAS-mutated cancers.
GENFIT's partner Ipsen is making strides with Iqirvo® (elafibranor) for PBC, with encouraging U.S. launch feedback and European reimbursement approvals.